Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
JCXH-108 by Immorna Hangzhou Biotechnology for Respiratory Syncytial Virus (RSV) Infections: Likelihood of Approval
JCXH-108 is under clinical development by Immorna Hangzhou Biotechnology and currently in Phase I for Respiratory Syncytial Virus (RSV) Infections....